New blockbuster vaccine increases sales and profits at drug giant GSK
A NEW blockbuster vaccine has boosted sales and profits at drug giant GSK.
Last May, Arexvy became the world's first approved vaccine for elderly patients with respiratory syncytial virus (RSV).
3Arexvy, the world's first approved…
Read More...
Read More...